Supplementary materials - Efficacy Of Dupilumab in Patients From China With Persistent Type 2 Asthma With and Without an Allergic Phenotype

Name: Supplementary materials - Efficacy Of Dupilumab in Patients From China With Persistent Type 2 Asthma With and Without an Allergic Phenotype
Creator: Qingling Zhang
Published: 2026-10-08T11:00:30.143Z
Keywords: Asthma, China, Asthma Exacerbation

Zhang, Qingling; Deng, Zhenan; Fu, Xiuhua; Fang, Haohui; Lin, Jie; Msihid, Jérôme; Huang, Yvonne; Kwah, Jason; Ledanois, Olivier; Zhong, Nanshan

doi:10.17632/sgfm46t8nd.2

Supplementary materials - Efficacy Of Dupilumab in Patients From China With Persistent Type 2 Asthma With and Without an Allergic Phenotype

Published: 8 October 2026| Version 2 | DOI: 10.17632/sgfm46t8nd.2

Contributors:

Qingling Zhang,

, Xiuhua Fu, Haohui Fang, Jie Lin,

, Yvonne Huang, Jason Kwah,

, Nanshan Zhong

Description

This appendix has been provided by the authors to give readers additional information about their work, the full text can be found online.

Files

Institutions

First Affiliated Hospital of Guangzhou Medical University
Guangdong, Guangzhou

Funders

Sanofi (United States)
New Jersey, Bridgewater
Grant ID: NCT03782532
Regeneron (United States)
New York, Tarrytown
Grant ID: NCT03782532

Supplementary materials - Efficacy Of Dupilumab in Patients From China With Persistent Type 2 Asthma With and Without an Allergic Phenotype

Description

Files

Institutions

Categories

Funders

Licence